IDEXX Laboratories Inc. (NASDAQ:IDXX) is considered one of the best medical technology stocks to invest in. Despite concerns about 2026 guidance, the company reported strong Q4 2025 earnings, with revenue of $1.09 billion and earnings per share of $3.08, beating analyst expectations. The companion animal business, IDEXX’s core segment, grew 15% driven by strong instrument revenue. For 2026, IDEXX expects revenue of $4.63-$4.72 billion and EPS of $14.29-$14.80. The company plans to offset headwinds with around 5,500 new InVueDx system placements next year. IDEXX develops, manufactures, and distributes diagnostic and information technology products for various markets.

Read more at Yahoo Finance: IDEXX Laboratories Inc. (IDXX) Shows Resilience as Analysts Reassess Targets